

## Ipilimumab

## Chemical Properties

CAS No. : 477202-00-9

Formula:

Molecular Weight: 145.38 kDa

Storage: Store at low temperature  
-20°C for 1 year

Actual storage temperature shall be subject to the COA.

## Ipilimumab

## Biological Description

Description	Ipilimumab (Yervoy) is an antibody inhibitor that blocks the inhibitory receptor cytotoxic T-lymphocyte antigen-4 (CTLA-4) on T cells, with immune-activating properties. Used for the treatment of unresectable or metastatic melanoma, this antibody exhibits antitumor activity.
Targets(IC50)	Others,Immunology/Inflammation related
In vitro	<b>Methods:</b> In a co-culture system of Jurkat T cells expressing CTLA-4 and Raji B cells, anti-CD3 antibody and gradient concentrations of Ipilimumab (0-100 µg/mL) were added, and luciferase activity driven by the IL-2 promoter was detected after 4 hours of incubation. <b>Results:</b> Ipilimumab concentration-dependently enhanced luciferase expression (up to approximately 3-fold), and replacing with Raji cells highly expressing CD80/CD86 eliminated the early inhibitory effect produced by low concentrations of Ipilimumab. [1]
In vivo	<b>Methods:</b> In an hCTLA-4 transgenic mouse MC-38 subcutaneous xenograft tumor model, Ipilimumab was administered by intraperitoneal injection at a dose of 10 mg/kg, twice weekly for 3 consecutive weeks (control group received PBS). <b>Results:</b> The Ipilimumab treatment group showed complete tumor regression in 2 out of 7 mice, comparable to the efficacy of pro- <i>Ipilimumab</i> , confirming its antitumor activity. [2]
Cell Research	Objective: Ipilimumab augments antitumor activity of bispecific antibody-armed T cells. Concentrations: 0, 0.5, 5.0, and 50 µg/mL. Incubation Time: 10-14 days. Method: hPBMC were stimulated with anti-CD3 monoclonal antibody with or without ipilimumab and expanded for 10-14 days. ATC were harvested and armed with anti-CD3 x anti-EGFR BiAb (EGFRBi) or anti-CD3 x anti-CD20 BiAb (CD20Bi) to test for redirected cytotoxicity against COLO356/FG pancreatic cancer cell line or Burkitt's lymphoma cell line (Daudi).
Animal Research	Objective: To investigate whether Ipilimumab and PD-1 antibody enhance the ability of T cells to control the outgrowth of EBV-induced lymphomas. Formulation: PBS. Dosages: 100 µg, three times weekly

### Preparing Stock Solutions

---

	<b>1mg</b>	<b>5mg</b>	<b>10mg</b>
1 mM	0.0069 mL	0.0344 mL	0.0688 mL
5 mM	0.0014 mL	0.0069 mL	0.0138 mL
10 mM	0.0007 mL	0.0034 mL	0.0069 mL
50 mM	0.0001 mL	0.0007 mL	0.0014 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481